 In-vivo CRISPRCas9 knock out gene editing treatments NTLA-2002 and NTLA-2001 have established proof of concept in treating patients with HAE and ATTR, respectively. Company has already gained the interest from big pharma for its CRISPRCas9 knock out gene editing technology platform from the likes of Regeneron and Novartis. 